While I select my investments based on return on investment, I select my charities based on impact. Year after year, Damon Runyon selects the best new minds in cancer research and funds their bold ideas for preventing and curing cancer. Year after year, its scientists go on to make major breakthroughs. That’s real impact.”
Cancer is a complex and dynamic foe. The Damon Runyon Board is committed to providing a framework for identifying, mentoring, and funding brilliant young scientists who have the talent and imagination to make paradigm-shifting strides in understanding and disrupting its mechanisms.”
CHAIR
Deborah J. Coleman*
Boston, Massachusetts
* Indicates member serves on the Scientific Committee
Vice Chair, Scientific Programs
William G. Kaelin, Jr., MD*
Sidney Farber Professor of Medicine
Dana-Farber Cancer Institute and
Harvard Medical School
Howard Hughes Medical Institute Investigator
Boston, Massachusetts
Vice Chair, Investments and Treasurer
David G. Marshall
Chairman and Chief Executive Officer
Amerimar Realty Company
Philadelphia, Pennsylvania
Vice Chair, Audit and Secretary
Sanford W. Morhouse, Esq.
Of Counsel
Schulte Roth & Zabel LLP
New York, New York
Vice Chair, Board Development
Michael L. Gordon*
Chief Executive Officer and
Chief Investment Officer
Angelo Gordon
New York, New York
Vice Chair
David M. Beirne
General Partner
X10 Capital
San Francisco, California
Vice Chair
Leon G. Cooperman
Chairman and Chief Executive Officer
Omega Operating, LLC
New York, New York
Vice Chair
Alan M. Leventhal
Chairman and Chief Executive Officer
Beacon Capital Partners, LLC
Boston, Massachusetts
Carlos Arteaga, MD*
Director of the Simmons Comprehensive Cancer Center
Associate Dean of Oncology Programs
University of Texas Southwestern Medical Center
Dallas, Texas
Steven J. Burakoff, MD*
Dean for Cancer Innovation
The Tisch Cancer Institute
Chief, Division of Pediatric Hematology and Oncology
Lillian and Henry M. Stratton Professor of
Cancer Medicine
Icahn School of Medicine at Mount Sinai
New York, New York
Robyn Coles
President
TRATE Properties LLC
Boston, Massachusetts
Gary E. Erlbaum
President
Greentree Properties
Ardmore, Pennsylvania
Thomas J. Fahey, Jr., MD*
Senior Vice President Emeritus
Memorial Sloan Kettering Cancer Center
New York, New York
Buck French
General Partner
X10 Capital
San Francisco, California
Elaine V. Fuchs, PhD*
Head, Laboratory of Mammalian Cell Biology and Development
Rebecca C. Lancefield Professor
The Rockefeller University
Howard Hughes Medical Institute Investigator
New York, New York
Levi Garraway,
MD, PhD*
Executive Vice President
Chief Medical Officer and Head of Product Development
Genentech, Inc.
South San Francisco, California
Richard B. Gaynor, MD*
President and Chief of Research and Development
BioNTech US
Cambridge, Massachusetts
Receiving a Damon Runyon Fellowship had a tremendous impact on my scientific career. I also have been fortunate to mentor new Damon Runyon scientists in my lab who have gone on to have exemplary independent careers. Damon Runyon builds generations of scientific leaders and mentors.”
Elaine V. Fuchs, PhD
(Damon Runyon Fellow ‘77-‘79)
Todd R. Golub, MD*
Director and Founding Core Institute Member
Broad Institute of MIT and Harvard
Charles A. Dana Investigator in Human Cancer Genetics
Dana-Farber Cancer Institute
Professor, Pediatrics
Harvard Medical School
Cambridge, Massachusetts
Scott Greenstein
President and Chief Content Officer
SiriusXM
New York, New York
Steve Hayden
Vice Chairman and Chief Creative Officer (Retired)
Ogilvy & Mather Worldwide
New York, New York
Morana Jovan-Embiricos, PhD*
Managing Partner
F2 Capital Ventures LLP
London, United Kingdom
Steven A. Kandarian
Chairman, President and Chief Executive Officer (Retired)
MetLife, Inc
North Palm Beach, Florida
Noah Knauf
General Partner
Bond Capital
San Francisco, California
Gabrielle Layton, PhD
Palo Alto, California
David M. Livingston, MD*
Emil Frei Distinguished Professor of Genetics and Medicine
Harvard Medical School and
Dana-Farber Cancer Institute
Boston, Massachusetts
Richard W. Meier
Director
The Bakewell Foundation
St. Louis, Missouri
John H. Myers
President (retired)
GE Asset Management
Fairfield, Connecticut
Richard J. O’Reilly, MD*
Claire L. Tow Chair, Pediatric Oncology Research
Memorial Sloan Kettering Cancer Center
New York, New York
Andrew S. Rachleff
President and Chief Executive Officer
Wealthfront, Inc.
Palo Alto, California
Meghan Raveis
Managing Director
William Raveis Charitable Fund
Shelton, Connecticut
Michael V. Seiden, MD, PhD*
President
The US Oncology Network
The Woodlands, Texas
Karen D. Seitz
Founder and Managing Director
Fusion Partners Global LLC
New York, New York
In Silicon Valley, we have witnessed brilliant young minds with bold ideas change the world. Damon Runyon makes this happen for cancer research. It identifies top emerging talent and encourages their high risk/high reward ideas. The payoff has been generations of game-changers.”
Andy and Debbie Rachleff
Nancy Simonian, MD*
Chief Executive Officer
Syros Pharmaceuticals, Inc.
Cambridge, Massachusetts
Cynthia Sulzberger
Wellington, Florida
Judy C. Swanson
Hillsborough, California
Nat Turner
Co-Founder and Chief Executive Officer
Flatiron Health
New York, New York
Peter Van Camp
Executive Chairman
Equinix, Inc.
Redwood City, California
James A. Wells, PhD*
Harry Wm. and Diana V. Hind
Distinguished Professor in Pharmaceutical Sciences
Professor, Molecular and Cellular Pharmacology
University of California, San Francisco
San Francisco, California
